Diagnostic Evaluation and Testing for Suspected Marfan Syndrome

Genetic Testing

Order FBN1 gene sequencing as the first‑line genetic test to identify pathogenic fibrillin‑1 mutations, which cause the majority of Marfan syndrome cases. The American Heart Association (AHA) recommends this as the primary molecular diagnostic step. 1
Approximately 12 % of FBN1 mutations are recurrent, and about 10 % of patients who meet clinical criteria for Marfan syndrome will have no detectable FBN1 mutation; therefore a negative result does not exclude the diagnosis. [2][3]
If FBN1 testing is negative, perform targeted testing of TGFBR1 and TGFBR2 because pathogenic variants in these genes can produce Marfan‑type (MFS2) or Loeys‑Dietz syndrome with overlapping phenotypes. 4

No specific blood panels are required for the diagnosis of Marfan syndrome; the evaluation relies on clinical findings and genetic testing. The AHA advises against ordering routine laboratory workup solely for Marfan assessment. 1

Transthoracic echocardiography (TTE) is mandatory at the initial visit to measure aortic root diameter at the sinuses of Valsalva, assess aortic regurgitation, and detect mitral valve prolapse. This is a core component of the AHA/ACC Marfan surveillance protocol. 5
Repeat TTE at 6 months to determine the rate of aortic growth; if stable, schedule annual TTE thereafter. This follow‑up schedule is endorsed by the AHA. [5][7]
After the baseline TTE, obtain a contrast‑enhanced CT or MRI of the thoracic aorta to confirm aortic dimensions and evaluate the entire aortic tree, especially when surgical planning is considered. Recommended by the AHA imaging guideline. 8

Perform a slit‑lamp examination with fully dilated pupils by an ophthalmologist experienced in connective‑tissue disorders to detect ectopia lentis (lens dislocation), a cardinal ocular manifestation of Marfan syndrome. The American Academy of Ophthalmology includes this in its Marfan evaluation recommendations. 9
Ectopia lentis is both sensitive and fairly specific for Marfan syndrome and helps differentiate it from Loeys‑Dietz syndrome, which may present with overlapping systemic features. 2

Conduct a thorough physical examination for skeletal features such as arachnodactyly, dolichostenomelia, pectus deformities, scoliosis, and joint laxity. These findings contribute to the systemic score used in the revised Ghent nosology. 1

Complete blood count (CBC) to screen for anemia when abnormal uterine bleeding is suspected in patients with menstrual irregularities. 3
Thyroid‑stimulating hormone (TSH) measurement to exclude thyroid dysfunction as a cause of menstrual disturbances. 8
Inflammatory markers (ESR, CRP) and a rheumatologic work‑up should be considered only if clinical signs suggest inflammatory arthritis (e.g., joint swelling, warmth, morning stiffness); these tests are not part of routine Marfan assessment. 3

Do not rely exclusively on genetic testing; about 10 % of definitively diagnosed patients lack an identifiable FBN1 mutation, underscoring the importance of clinical criteria. 2
Avoid ordering extensive laboratory panels for Marfan evaluation, as they do not contribute to diagnosis and may lead to unnecessary testing. 1
Ensure multidisciplinary evaluation—cardiology (TTE/CT/MRI) and ophthalmology (slit‑lamp exam) are essential components of the diagnostic work‑up, as emphasized by the AHA and ophthalmology societies. [3][9]
Family history of a first‑degree relative with Marfan syndrome significantly influences diagnostic criteria and should be systematically obtained. 2